In conclusion, we propose the use of SCCA-IgM (with the newly identified 120 AU/mL cut-off) to help categorize patients with liver cirrhosis into different risk classes, hence guide clinical decisions like intensity of surveillance and prevention strategies. This evidence concerns the gene CD40LG and cirrhosis of liver.